Vis enkel innførsel

dc.contributor.authorAstrup, Guro Lindviksmoen
dc.contributor.authorRohde, Gudrun E.
dc.contributor.authorRimehaug, Stein Arne
dc.contributor.authorAndersen, Marit Helen
dc.contributor.authorBernklev, Tomm
dc.contributor.authorBjordal, Kristin
dc.contributor.authorFalk, Ragnhild Sørum
dc.contributor.authorJørgensen, Nina Marie Høyning
dc.contributor.authorStavem, Knut
dc.contributor.authorTollisen, Anita
dc.contributor.authorAmdal, Cecilie Delphin
dc.date.accessioned2022-03-31T11:57:30Z
dc.date.available2022-03-31T11:57:30Z
dc.date.created2021-08-10T09:48:49Z
dc.date.issued2021
dc.identifier.citationAstrup, G.L., Rohde, G., Rimehaug, S.A., Andersen, M.H., Bernklev, T., Bjordal, K., Sørum Falk, R., Høyning Jørgensen, N.M., Stavem, K., Tollisen, A., Amdal, C.D. (2021) Comparing the use of patient-reported outcomes in clinical studies in Europe in 2008 and 2018: a literature review. Quality of Life Research, 31, 659–669en_US
dc.identifier.issn1573-2649
dc.identifier.urihttps://hdl.handle.net/11250/2988845
dc.description.abstractPurpose Several guidelines for the use of patient-reported outcomes (PROs) in clinical studies have been published in the past decade. This review primarily aimed to compare the number and compliance with selected PRO-specifc criteria for reporting of clinical studies in Europe using PROs published in 2008 and 2018. Secondarily, to describe the study designs, PRO instruments used, patient groups studied, and countries where the clinical studies were conducted. Methods A literature search was conducted in MEDLINE to identify eligible publications. To assess the number of publications, all abstracts were screened for eligibility by pairs of reviewers. Compliance with PRO-specifc criteria and other key characteristics was assessed in a random sample of 150 eligible full-text publications from each year. Randomized controlled trials (RCTs) were assessed according to the full CONSORT-PRO checklist. Results The search identifed 1692 publications in 2008 and 4290 in 2018. After screening of abstracts, 1240 from 2008 and 2869 from 2018 were clinical studies using PROs. By full-text review, the proportion of studies discussing PRO-specifc limitations and implications was higher in 2018 than in 2008, but there were no diferences in the other selected PRO-specifc criteria. In 2018, a higher proportion of studies were longitudinal/cohort studies, included≥300 patients, and used electronic administration of PRO than in 2008. The most common patient groups studied were those with cancer or diseases of the musculoskeletal system or connective tissue. Conclusion The number of clinical studies from Europe using PROs was higher in 2018 than in 2008, but there was little diference in compliance with the PRO-specifc criteria. The studies varied in terms of study design and PRO instruments used in both publication years.en_US
dc.language.isoengen_US
dc.publisherSpringer Natureen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleComparing the use of patient-reported outcomes in clinical studies in Europe in 2008 and 2018: a literature review.en_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.rights.holder© 2021 The Author(s)en_US
dc.subject.nsiVDP::Medisinske Fag: 700en_US
dc.source.pagenumber659-669en_US
dc.source.volume31en_US
dc.source.journalQuality of Life Researchen_US
dc.identifier.doihttps://doi.org/10.1007/s11136-021-02946-7
dc.identifier.cristin1924904
cristin.qualitycode2


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal